Monitoring Schedule Serum IGF-1 at baseline and at 8-12 weeks Fasting glucose at baseline and every 3-6 months (GH increases insulin resistance acutely) Thyroid panel at baseline (hypothyroidism blunts IGF-1 response) Blood pressure and fluid retention assessment at each visit The American Association of Clinical Endocrinology (AACE) recommends IGF-1 be kept within the age- and sex-adjusted reference range during any GH-stimulating therapy to minimize risk of adverse effects including fluid retention and glucose intolerance [9]
Each transition in our proposed algorithm is grounded in trial evidence, guideline thresholds, and comparative safety/efficacy profiles
Phase 2 clinical trials showed some positive outcomes, but these were not sufficiently significant over a treatment period of 7-10 days, leading to the halt of development [11, 12]
doi: 10.1093/emboj/17.17.4987
NiceRx-affiliated clinicians use lower, gentler dosing to support effective weight loss with fewer unwanted side effects
What medical conditions or health history would disqualify someone from using Sermorelin